BROSSARD, QUEBEC -- (Marketwired) -- 06/19/13 -- DIAGNOS Inc. ("DIAGNOS" or "the Corporation") (TSX VENTURE: ADK), a leader in the use of artificial intelligence and advanced knowledge extraction techniques, announces today a grant of a total of 300,000 stock options to four officers of the Corporation as approved by the board of directors under the terms of the Corporation's stock option plan.
Grants of stock options vest at the rate of 33.33% per year, commencing with the first anniversary of the grant. The exercise price of these options has been established at $0.10 per share. The expiry date to which these options can be exercised has been fixed to June 18, 2018.
All monies quoted in this press release shall be stated in lawful money of Canada.
Founded in 1998, DIAGNOS is a publicly traded Canadian corporation (TSX VENTURE: ADK), with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com.
Bid Capital Markets
Most Popular Stories
- Obama Administration Releases Proposal to Regulate For-Profit Colleges
- Some California Cities Seeking Water Independence
- Apple, HP, Intel May Take a Hit from Slowdown in Smartphone Sales Growth
- Chinese e-Commerce Giant Alibaba Gears for IPO in U.S.
- FDIC Files Lawsuit on Behalf of Banks Allegedly Hurt by Libor Scandal
- Motley Crue's Nikki Sixx Marries Model Courtney Bingham
- Will Missing Malaysian Jet Prompt Aviation System Change?
- SoCalGas Reaches Record Spend on Diversity Suppliers
- Keurig Adds Peet's coffee, Alters Starbucks deal
- Obama Seeks to Stay Neutral in CIA-Senate Conflict